Funding news · Nov 13, 2026

Boston Medical Sciences Raises ¥34.98B Series B Led by Beyond Next Ventures

Boston Medical Sciences Secures Series B Funding

Boston Medical Sciences, a Tokyo-based medical AI startup, has raised a Series B round totaling ¥34,979,364 (JPY). The funding date is recorded as November 13, 2026. Beyond Next Ventures led the round, with participation from Global Brain Corporation, Daiwa House Ventures, and Nippon Growth Capital Investment Corporation.

Company Background

Founded in April 2023, Boston Medical Sciences was established by physicians who teach and research at Harvard Medical School and Massachusetts General Hospital. The company operates at the intersection of clinical practice and artificial intelligence, focusing on reducing friction in diagnostic imaging workflows.

Product Focus: AIM4CRC

The company's flagship system, AIM4CRC, is a laxative-free virtual colonoscopy platform. It combines colon CT imaging with AI algorithms for bowel cleansing and polyp detection, with the goal of removing the preparation burden associated with conventional colon exams.

Key development milestones include:

  • Completion of a Japanese clinical trial for the AIM4CRC system.
  • Receipt of US FDA Breakthrough Device Designation in May 2026.
  • Ongoing preparation for commercialization in both Japan and the United States.

Funding Stage and Investor Profile

The Series B round places Boston Medical Sciences among Tokyo-based medical AI companies that have progressed beyond early-stage financing. The lead investor, Beyond Next Ventures, is joined by Global Brain Corporation, Daiwa House Ventures, and Nippon Growth Capital Investment Corporation.

Acquisition Relevance

The combination of a completed Japanese clinical trial, FDA Breakthrough Device Designation, and a defined commercialization path in two major markets makes Boston Medical Sciences a company to watch in the virtual colonoscopy and gastrointestinal imaging segment. The Series B capital is positioned against a product that targets prep burden, a long-standing barrier to colorectal screening adherence.

For strategic acquirers in medical imaging, diagnostics, or gastrointestinal care, Boston Medical Sciences offers a clinically validated AI platform with regulatory traction in both Japan and the US.

© 2026 VeilStrat. All rights reserved.All systems operational